Mineralocorticoid receptor antagonists and the metabolic syndrome

Current Hypertension Reports

Volumn 12, Issue 4, 2010, Pages 252-257

  Tirosh, Amir ^a   Garg, Rajesh ^a   Adler, Gail K ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Aldosterone; Eplerenone; Insulin resistance; Mineralocorticoid receptor; Obesity; Spironolactone

Indexed keywords

ALDOSTERONE; ALISKIREN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EPLERENONE; GLUCOSE TRANSPORTER 2; GLUCOSE TRANSPORTER 4; INSULIN RECEPTOR SUBSTRATE 1; INSULIN RECEPTOR SUBSTRATE 2; INTERCELLULAR ADHESION MOLECULE 1; LIPID; MINERALOCORTICOID; MINERALOCORTICOID ANTAGONIST; MINERALOCORTICOID RECEPTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PLACEBO; SPIRONOLACTONE;

ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; DIABETIC NEPHROPATHY; HEART FAILURE; HUMAN; HYPERTENSION; INFLAMMATION; INSULIN RESISTANCE; LIPID PEROXIDATION; METABOLIC SYNDROME X; NONHUMAN; OBESITY; PATHOGENESIS; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RENOVASCULAR DISEASE; REVIEW; SIGNAL TRANSDUCTION; STROKE;

ALDOSTERONE; ALDOSTERONE ANTAGONISTS; ANTIHYPERTENSIVE AGENTS; HUMANS; HYPERTENSION; INFLAMMATION; INSULIN RESISTANCE; LIPID METABOLISM; LIPIDS; METABOLIC SYNDROME X; OBESITY; RECEPTORS, MINERALOCORTICOID; SIGNAL TRANSDUCTION; SPIRONOLACTONE;

EID: 77956265232     PISSN: 15226417     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11906-010-0126-2     Document Type: Review

References (50)

1. AM McNeill WD Rosamond CJ Girman, et al. 2005 The metabolic syndrome and 11-year risk of incident cardiovascular disease in the Atherosclerosis Risk in Communities study Diabetes Care 28 385 390 10.2337/diacare.28.2.385 15677797
2. J Chen P Muntner LL Hamm, et al. 2004 The metabolic syndrome and chronic kidney disease in U.S. adults Ann Intern Med 140 167 174 14757614
3. PW Wilson RB D'Agostino H Parise, et al. 2005 Metabolic syndrome as a precursor of cardiovascular disease and type 2 diabetes mellitus Circulation 112 3066 3072 10.1161/CIRCULATIONAHA.105.539528 1:CAS:528:DC%2BD2MXhtF2rtbfL 16275870
4. J Wang K Sarnola S Ruotsalainen, et al. 2010 The metabolic syndrome predicts incident congestive heart failure: a 20-year follow-up study of elderly Finns Atherosclerosis 210 237 242 10.1016/j.atherosclerosis.2009.10.042 1:CAS:528:DC%2BC3cXlsFOgur4%3D 19945701
5. J Wang S Ruotsalainen L Moilanen, et al. 2007 The metabolic syndrome predicts cardiovascular mortality: a 13-year follow-up study in elderly non-diabetic Finns Eur Heart J 28 857 864 10.1093/eurheartj/ehl524 17303589
6. SG Wannamethee AG Shaper L Lennon RW Morris 2005 Metabolic syndrome vs Framingham Risk Score for prediction of coronary heart disease, stroke, and type 2 diabetes mellitus Arch Intern Med 165 2644 2650 10.1001/archinte.165.22.2644 16344423
7. A Odermatt AG Atanasov 2009 Mineralocorticoid receptors: emerging complexity and functional diversity Steroids 74 163 171 10.1016/j.steroids.2008. 10.010 1:CAS:528:DC%2BD1MXhtFentrs%3D 19022273
8. C Grossmann M Gekle 2009 New aspects of rapid aldosterone signaling Mol Cell Endocrinol 308 53 62 10.1016/j.mce.2009.02.005 1:CAS:528: DC%2BD1MXnsFantL8%3D 19549592
9. KK Gaddam E Pimenta S Husain DA Calhoun 2009 Aldosterone and cardiovascular disease Curr Probl Cardiol 34 51 84 10.1016/j.cpcardiol.2008.10. 002 19135616
10. NJ Brown 2008 Aldosterone and vascular inflammation Hypertension 51 161 167 10.1161/HYPERTENSIONAHA.107.095489 1:CAS:528:DC%2BD1cXmt1OhsQ%3D%3D 18172061
11. JW Funder 2009 Reconsidering the roles of the mineralocorticoid receptor Hypertension 53 286 290 10.1161/HYPERTENSIONAHA.108.119966 1:CAS:528: DC%2BD1MXlvFSrsQ%3D%3D 19139379
12. JA Leopold A Dam BA Maron, et al. 2007 Aldosterone impairs vascular reactivity by decreasing glucose-6-phosphate dehydrogenase activity Nat Med 13 189 197 10.1038/nm1545 1:CAS:528:DC%2BD2sXhsVykur0%3D 17273168
13. S Shibata M Nagase S Yoshida, et al. 2008 Modification of mineralocorticoid receptor function by Rac1 GTPase: implication in proteinuric kidney disease Nat Med 14 1370 1376 10.1038/nm.1879 1:CAS:528:DC%2BD1cXhsVWgsr7L 19029984
14. CA Lemarie SM Simeone A Nikonova, et al. 2009 Aldosterone-induced activation of signaling pathways requires activity of angiotensin type 1a receptors Circ Res 105 852 859 10.1161/CIRCRESAHA.109.196576 1:CAS:528:DC%2BD1MXhsVCiurrP 19762686
15. B Pitt F Zannad WJ Remme, et al. 1999 The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators N Engl J Med 341 709 717 10.1056/NEJM199909023411001 1:CAS:528:DyaK1MXmtVyrurk%3D 10471456
16. B Pitt W Remme F Zannad, et al. 2003 Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction N Engl J Med 348 1309 1321 10.1056/NEJMoa030207 1:CAS:528: DC%2BD3sXis1ehurY%3D 12668699
17. NC Edwards RP Steeds PM Stewart, et al. 2009 Effect of spironolactone on left ventricular mass and aortic stiffness in early-stage chronic kidney disease: a randomized controlled trial J Am Coll Cardiol 54 505 512 10.1016/j.jacc.2009.03.066 1:CAS:528:DC%2BD1MXhtFaisLfP 19643310
18. B Pitt N Reichek R Willenbrock, et al. 2003 Effects of eplerenone, enalapril, and eplerenone/enalapril in patients with essential hypertension and left ventricular hypertrophy: the 4E-left ventricular hypertrophy study Circulation 108 1831 1838 10.1161/01.CIR.0000091405.00772.6E 1:CAS:528:DC%2BD3sXnvVajur8%3D 14517164
19. UF Mehdi B Adams-Huet P Raskin, et al. 2009 Addition of angiotensin receptor blockade or mineralocorticoid antagonism to maximal angiotensin-converting enzyme inhibition in diabetic nephropathy J Am Soc Nephrol 20 2641 2650 10.1681/ASN.2009070737 1:CAS:528:DC%2BD1MXhs1Witb3P 19926893
20. R Bentley-Lewis G Adler T Perlstein, et al. 2007 Body Mass Index Predicts Aldosterone Production in Normotensive Adults on a High-Salt Diet J Clin Endocrinol Metab 92 4472 4475 10.1210/jc.2007-1088 1:CAS:528:DC%2BD2sXhtlartbjK 17726083
21. M Caprio B Feve A Claes, et al. 2007 Pivotal role of the mineralocorticoid receptor in corticosteroid-induced adipogenesis FASEB J 21 2185 2194 10.1096/fj.06-7970com 1:CAS:528:DC%2BD2sXnvVagtr8%3D 17384139
22. V Lamounier-Zepter M Ehrhart-Bornstein SR Bornstein 2005 Mineralocorticoid-stimulating activity of adipose tissue Best Pract Res Clin Endocrinol Metab 19 567 575 10.1016/j.beem.2005.07.002 1:CAS:528: DC%2BD2MXht1GhsLnO 16311217
23. M Ehrhart-Bornstein V Lamounier-Zepter A Schraven, et al. 2003 Human adipocytes secrete mineralocorticoid-releasing factors Proc Natl Acad Sci U S A 100 14211 14216 10.1073/pnas.2336140100 1:CAS:528:DC%2BD3sXpsFGiur4%3D 14614137
24. TL Goodfriend BM Egan DE Kelley 1999 Plasma aldosterone, plasma lipoproteins, obesity and insulin resistance in humans Prostaglandins Leukot Essent Fatty Acids 60 401 405 10.1016/S0952-3278(99)80020-9 1:CAS:528: DyaK1MXltleltrc%3D 10471129
25. S Engeli J Bohnke K Gorzelniak, et al. 2005 Weight loss and the renin-angiotensin-aldosterone system Hypertension 45 356 362 10.1161/01.HYP.0000154361.47683.d3 1:CAS:528:DC%2BD2MXhtlOis7k%3D 15630041
26. E Ferrannini G Seghieri E Muscelli 1994 Insulin and the renin-angiotensin-aldosterone system: influence of ACE inhibition J Cardiovasc Pharmacol 24 Suppl 3 S61 S69 1:CAS:528:DyaK2MXitlCisbc%3D 7700069
27. J Pierluissi FO Navas SJ Ashcroft 1986 Effect of adrenal steroids on insulin release from cultured rat islets of Langerhans Diabetologia 29 119 121 10.1007/BF00456122 1:CAS:528:DyaL28XhvVSgtb0%3D 3516767
28. J Matrozova O Steichen L Amar, et al. 2009 Fasting plasma glucose and serum lipids in patients with primary aldosteronism: a controlled cross-sectional study Hypertension 53 605 610 10.1161/HYPERTENSIONAHA.108.122002 1:CAS:528:DC%2BD1MXivVemtrw%3D 19221213
29. Catena C, Colussi G, Di Fabio A, et al.: Mineralocorticoid antagonists treatment versus surgery in primary aldosteronism. Horm Metab Res 2010 Jan 29 (Epub ahead of print).
30. G Giacchetti LA Sechi S Rilli RM Carey 2005 The renin-angiotensin- aldosterone system, glucose metabolism and diabetes Trends Endocrinol Metab 16 120 126 10.1016/j.tem.2005.02.003 1:CAS:528:DC%2BD2MXivV2gs7o%3D 15808810
31. C Catena R Lapenna S Baroselli, et al. 2006 Insulin sensitivity in patients with primary aldosteronism: a follow-up study J Clin Endocrinol Metab 91 3457 3463 10.1210/jc.2006-0736 1:CAS:528:DC%2BD28XpslajtLg%3D 16822818
32. F Fallo P Della Mea N Sonino, et al. 2007 Adiponectin and insulin sensitivity in primary aldosteronism Am J Hypertens 20 855 861 10.1016/j.amjhyper.2007.03.012 1:CAS:528:DC%2BD2sXosF2hur4%3D 17679033 Patients with primary aldosteronism had more insulin resistance (higher HOMA index) and lower levels of adiponectin than patients with low-renin essential hypertension in the absence of MetS
33. G Sindelka J Widimsky T Haas, et al. 2000 Insulin action in primary hyperaldosteronism before and after surgical or pharmacological treatment Exp Clin Endocrinol Diabetes 108 21 25 1:CAS:528:DC%2BD3cXitFejt70%3D 10768828
34. R Garg S Hurwitz GH Williams, et al. 2010 Aldosterone production and insulin resistance in healthy adults J Clin Endocrinol Metab 95 1986 1990 10.1210/jc.2009-2521 1:CAS:528:DC%2BC3cXltFSntr4%3D 20130077 In normotensive healthy adults, high angiotensin II-stimulated aldosterone level was an independent predictor of insulin resistance even after adjusting for age, body mass index, and diastolic blood pressure
35. EM Freel IK Tsorlalis JD Lewsey, et al. 2009 Aldosterone status associated with insulin resistance in patients with heart failure-data from the ALOFT study Heart 95 1920 1924 10.1136/hrt.2009.173344 1:CAS:528: DC%2BC3cXivVCgur0%3D 19713201
36. J Selvaraj T Muthusamy C Srinivasan K Balasubramanian 2009 Impact of excess aldosterone on glucose homeostasis in adult male rat Clin Chim Acta 407 51 57 10.1016/j.cca.2009.06.030 1:CAS:528:DC%2BD1MXpt1KisLc%3D 19567248
37. JF Ndisang N Lane A Jadhav 2009 The heme oxygenase system abates hyperglycemia in Zucker diabetic fatty rats by potentiating insulin-sensitizing pathways Endocrinology 150 2098 2108 10.1210/en.2008-0239 1:CAS:528: DC%2BD1MXlsFCjtLw%3D 19106228
38. C Guo V Ricchiuti BQ Lian, et al. 2008 Mineralocorticoid receptor blockade reverses obesity-related changes in expression of adiponectin, peroxisome proliferator-activated receptor-gamma, and proinflammatory adipokines Circulation 117 2253 2261 10.1161/CIRCULATIONAHA.107.748640 1:CAS:528:DC%2BD1cXkvFSjtL4%3D 18427128 In obese, db/db mice, MR blockade reduced circulating triglyceride levels, decreased adipose tissue expression of inflammatory cytokines, and increased expression of adiponectin and PPARγ. In 3 T3-L1 preadipocytes, aldosterone increased expression of inflammatory cytokines and decreased expression of adiponectin and PPARγ, supporting a direct effect of aldosterone on gene expression
39. A Hirata N Maeda A Hiuge, et al. 2009 Blockade of mineralocorticoid receptor reverses adipocyte dysfunction and insulin resistance in obese mice Cardiovasc Res 84 164 172 10.1093/cvr/cvp191 1:CAS:528:DC%2BD1MXhtFarsbnP 19505930 In obese, db/db and ob/ob mice, MR blockade reduced insulin resistance and improved adipose tissue inflammation (decreased reactive oxygen species and macrophage infiltration). In 3 T3-L1 adipocytes, aldosterone increased intracellular reactive oxygen species
40. C Calle J Campion M Garcia-Arencibia, et al. 2003 Transcriptional inhibition of the human insulin receptor gene by aldosterone J Steroid Biochem Mol Biol 84 543 553 10.1016/S0960-0760(03)00072-4 1:CAS:528:DC%2BD3sXktFCqt7g%3D 12767279
41. T Wada S Ohshima E Fujisawa, et al. 2009 Aldosterone inhibits insulin-induced glucose uptake by degradation of insulin receptor substrate (IRS) 1 and IRS2 via a reactive oxygen species-mediated pathway in 3 T3-L1 adipocytes Endocrinology 150 1662 1669 10.1210/en.2008-1018 1:CAS:528: DC%2BD1MXktVWmu7Y%3D 19095745 Aldosterone treatment in the adipocyte cell line resulted in IRS-1 serine phosphorylation and degradation, leading to decreased insulin stimulation of both Akt activation and glucose uptake. This mechanism was suggested to involve aldosterone-mediated intracellular oxidative stress
42. Sato A, Fukuda S: Clinical effects of eplerenone, a selective aldosterone blocker, in Japanese patients with essential hypertension. J Hum Hypertens 2009 Oct 29 (Epub ahead of print).
43. T Wada H Kenmochi Y Miyashita, et al. 2010 Spironolactone improves glucose and lipid metabolism by ameliorating hepatic steatosis and inflammation and suppressing enhanced gluconeogenesis induced by high-fat and high-fructose diet Endocrinology 151 2040 2049 10.1210/en.2009-0869 1:CAS:528: DC%2BC3cXlsFKgsr8%3D 20211973 MR blockade improved glucose metabolism (assessed by the glucose tolerance test and insulin tolerance test), reduced triglyceride and cholesterol levels, reduced hepatic inflammation (decreased hepatic expression of TNFα, interleukin-6, and MCP-1), and reduced hepatic steatosis in mice fed a high-fat and high-fructose diet
44. B Kirilmaz F Asgun E Alioglu, et al. 2010 High inflammatory activity related to the number of metabolic syndrome components J Clin Hypertens (Greenwich) 12 136 144 10.1111/j.1751-7176.2009.00229.x 1:CAS:528: DC%2BC3cXivFWntLg%3D
45. M Caprio BG Newfell A la Sala, et al. 2008 Functional mineralocorticoid receptors in human vascular endothelial cells regulate intercellular adhesion molecule-1 expression and promote leukocyte adhesion Circ Res 102 1359 1367 10.1161/CIRCRESAHA.108.174235 1:CAS:528:DC%2BD1cXmt1yhtrs%3D 18467630
46. R Limor M Kaplan O Sharon, et al. 2009 Aldosterone up-regulates 12- and 15-lipoxygenase expression and LDL oxidation in human vascular smooth muscle cells J Cell Biochem 108 1203 1210 10.1002/jcb.22352 1:CAS:528: DC%2BD1MXhsV2gsLrK 19795383 Treating vascular smooth muscle cells with aldosterone resulted in increased expression of 12- and 15-lipoxygenase expression and increased LDL oxidation. These effects were blocked by MR antagonists or an EGF-receptor antagonist, demonstrating potential interactions between these two receptors
47. HV Joffe RY Kwong MD Gerhard-Herman, et al. 2007 Beneficial effects of eplerenone versus hydrochlorothiazide on coronary circulatory function in patients with diabetes mellitus J Clin Endocrinol Metab 92 2552 2558 10.1210/jc.2007-0393 1:CAS:528:DC%2BD2sXotVylsL4%3D 17488800
48. H Izawa T Murohara K Nagata, et al. 2005 Mineralocorticoid receptor antagonism ameliorates left ventricular diastolic dysfunction and myocardial fibrosis in mildly symptomatic patients with idiopathic dilated cardiomyopathy: a pilot study Circulation 112 2940 2945 1:CAS:528:DC%2BD2MXhtFKqtrvI 16275882
49. AM Grandi D Imperiale R Santillo, et al. 2002 Aldosterone antagonist improves diastolic function in essential hypertension Hypertension 40 647 652 10.1161/01.HYP.0000036399.80194.D8 1:CAS:528:DC%2BD38XotFWltLc%3D 12411457
50. The NAVIGATOR Study Group 2010 Effect of valsartan on the incidence of diabetes and cardiovascular events N Engl J Med 363 1477 1490 10.1056/NEJMoa1001121 In this large, placebo-controlled, randomized trial among patients with impaired glucose tolerance (many of whom met the MetS diagnostic criteria), the use of valsartan for 5 years led to a relative reduction of 14% in the incidence of diabetes. This study supports a role for blockade of the RAAS in preventing progression to diabetes